
Xbrane Biopharma Q3 2023 - Standing before a critical year

Redeye adjusts its estimates and fair value range for Xbrane Biopharma following its Q3 2023 report, which prompted a substantial decline in the share price. The anticipated near-term deals for the Ximluci and Xdivane projects should however alleviate these concerns and improve the company's financial prospects.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Xbrane Biopharma Q3 2023 - Standing before a critical year](#)